KROS
Keros Therapeutics Inc
11.60$
+3.8%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Cash Flow
Keros Therapeutics Inc (KROS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -20 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.5 | -5.0 | -3.0 | -5.5 | -8.1 | -9.9 | -11 | -8.0 | -11 | -18 | -14 | -20 | -1.4 | -23 | -25 | -21 | -34 | -31 | -34 | -25 | -45 | -40 | -31 | -46 | 161 | -30 | 3.2 | -27 | -3.5 | -20 | -48 | |
| 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 1.6 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | 1.4 | 1.5 | 2.5 | 2.8 | 3.1 | 3.3 | 4.4 | 4.8 | 4.8 | 4.7 | 5.7 | 7.0 | 8.7 | 7.3 | 8.1 | 8.8 | 8.8 | 9.2 | 8.9 | 8.5 | 4.0 | 7.3 | 6.2 | 5.4 | 23 | |
| 0.7 | 0.7 | 0.6 | – | 1.6 | 1.2 | 1.5 | 1.6 | 2.5 | 3.0 | 2.5 | 3.3 | 4.4 | 4.8 | 4.8 | 4.7 | 5.7 | 7.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | -2.9 | -0.1 | -3.7 | 2.1 | -0.5 | -0.4 | 1.0 | 2.7 | -5.1 | 3.3 | -17 | 18 | -0.6 | -6.2 | 3.1 | -4.8 | -0.9 | -3.8 | 6.9 | -10 | -4.0 | 13 | -10 | 2.9 | -8.4 | 5.5 | -12 | 13 | 1.9 | 8.2 | |
| 0.0 | 0.2 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.2 | 0.5 | 0.1 | 0.2 | 0.1 | 0.6 | 0.2 | 0.4 | 1.1 | 0.3 | 0.6 | 0.5 | 0.9 | 0.3 | 0.4 | 0.3 | 0.6 | 0.7 | 0.1 | 0.1 | 0.1 | 0.2 | 0.5 | |
| -0.2 | -0.2 | -0.1 | 0.0 | -0.2 | 0.0 | 0.0 | -0.1 | -0.2 | -0.5 | -0.1 | -0.2 | -0.1 | -0.6 | -0.2 | -0.4 | -1.1 | -0.3 | -0.6 | -0.5 | -0.9 | -0.3 | -0.4 | -0.3 | -0.6 | -0.7 | -0.1 | -0.1 | -0.1 | -0.2 | -0.5 | |
| – | – | – | – | 56 | 103 | – | -103 | -103 | 0.1 | 0.0 | 28 | 0.1 | 10 | 49 | 61 | 108 | 1.7 | – | – | – | – | – | – | – | – | 0.1 | – | – | – | – | |
| 0.0 | 0.0 | 0.0 | 0.0 | 56 | 100 | 0.0 | 140 | 0.0 | 0.1 | 0.0 | 28 | 0.1 | 10 | 49 | 61 | 108 | 1.7 | 0.3 | 69 | 157 | 3.5 | 156 | 76 | 0.0 | 0.0 | 0.1 | -379 | -2.3 | -3.3 | -384 | |
| -2.5 | -5.2 | -3.0 | -5.5 | 47 | 90 | -11 | 132 | -11 | -18 | -16 | 8.7 | -1.5 | -13 | 24 | 40 | 72 | -29 | -34 | 43 | 111 | -37 | 125 | 29 | 161 | -30 | 3.3 | -406 | -5.9 | -24 | -433 | |
| -2.5 | -5.2 | -3.0 | -5.5 | -8.3 | -10.0 | -11 | -8.1 | -11 | -18 | -15 | -20 | -1.6 | -23 | -25 | -22 | -35 | -31 | -35 | -26 | -46 | -40 | -31 | -46 | 161 | -30 | 3.1 | -27 | -3.6 | -21 | -48 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.